4 Comments
 

Based on the most helpful WSO content, compensation in Biotech/Therapeutics Equity Research (ER) can vary significantly depending on the level of experience, but it generally does not match the levels seen in Investment Banking (IB). Here's a breakdown of IB compensation for comparison:

  • Director/MD: $592K
  • Vice President: $392K
  • Associates: $260K
  • 3rd+ Year Analyst: $187K
  • 2nd Year Analyst: $169K
  • 1st Year Analyst: $168K
  • Intern/Summer Associate: $167K
  • Intern/Summer Analyst: $94K

While Biotech ER compensation is competitive, it typically trails IB, especially at the higher levels. However, Biotech ER offers unique opportunities, such as deeper specialization in a niche field and potentially better work-life balance compared to IB.

Sources: Work/Life Balance: Equity Research vs. Investment Banking - (A Definitive Guide, Part 1), Exits for biotech/biopharma/life sciences IB, Request for a preclinical biotech pharma model, Divergence in the Drug Businesses: Pharmaceuticals and Biotechnology, JPMorgan ER vs Wells Fargo Investment Banking

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

The compensation system in the biotechnology (Biotech) sector is truly unique, but it differs fundamentally from that of investment banking. While banking focuses on short-term cash bonuses from closing deals, the biotechnology sector is tied to long-term research phases and FDA drug approvals, so the main driver of wealth here is equity (Equity/Options).

 

Laborum provident quod voluptatem dolore labore. Deserunt eveniet quia aut dignissimos maxime corrupti iusto.

Perferendis rem dolor tenetur quis tempore. Doloribus commodi explicabo ut illum doloremque commodi beatae unde. Enim vero accusantium necessitatibus similique tempora qui nobis.

Officia incidunt mollitia cumque id optio veniam. Dolor odio rerum maiores itaque. Asperiores et ipsa aut in aut. Voluptas praesentium ullam consequuntur et possimus. Consequatur autem ipsam ut et fugiat nisi rerum. Quasi qui ut sed fuga quas quia. Maiores rerum minima voluptatem suscipit.

Rem amet dolorem qui. Quia ducimus aliquid sunt molestiae. Voluptas voluptatibus et ex ullam commodi adipisci nam. Aut rerum et amet voluptatem quia. Nemo ratione tempora sed aperiam esse officiis officia.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
DrApeman's picture
DrApeman
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”